Spruce Biosciences, Inc. Common StockSPRB
▼ NegativeCapitalrelevance
Reports Q2 GAAP EPS of -$6.68, a significant loss.
Impact on stocks 1
Biotech & Genomic Medicine
Spruce Biosciences, Inc. Common StockSpruce Biosciences reported a second-quarter GAAP net loss of $6.68 per share. Cash and cash equivalents stood at $96.3 million as of June 30, 2026, up from $48.9 million at the end of 2025. The company believes its current cash position will be sufficient to fund planned operations and debt obligations into the second half of 2027.
Spruce Biosciences, Inc. Common StockReports Q2 GAAP EPS of -$6.68, a significant loss.